Potential regional differences for the tolerability profiles of fluoropyrimidines Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Deoxycytidine
  • Fluorouracil
  • Gastrointestinal Diseases
  • Neutropenia
  • Prodrugs

abstract

  • Regional differences exist in the tolerability profiles of fluoropyrimidines. More treatment-related toxicity was reported in the US compared with the rest of the world for bolus FU/LV and capecitabine in first-line MCRC and adjuvant colon cancer. In the adjuvant setting, a range of fluoropyrimidine tolerability was observed, with East Asian patients having the lowest, and US patients the highest, RR.

publication date

  • September 22, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.15.2090

PubMed ID

  • 18445840

Additional Document Info

start page

  • 2118

end page

  • 23

volume

  • 26

number

  • 13